Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Klawans, H. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Klawans, H. L.
NEUROLOGY 1985;35:749
© 1985 American Academy of Neurology

Chronic agonist therapy for Parkinson's disease

A 5-year study of bromocriptine and pergolide

Christopher G. Goetz, MD, Caroline M. Tanner, MD, Russell H. Glantz, MD and Harold L. Klawans, MD

Department of Neurological Sciences, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.

We used pergolide to treat 10 patients with idiopathic Parkinson's disease who had first responded to, and then failed, bromocriptine therapy. At the end of 5 years, patients had improved when compared with study entry. Peak efficacy, equal with both drugs, was seen at 12 months. After a mean treatment of 29 months, bromocriptine was no longer effective, but pergolide was still beneficial.

Address correspondence and reprint requests to Dr. Goetz, Department of Neurological Sciences, Rush-Presbyterian St. Luke's Medical Center, 1725 West Harrison, Chicago, IL 60612.

Supported by United Parkinson Foundation and Boothroyd Foundation, Chicago, and Eli Lilly and Sandoz Pharmaceuticals.

Dr. Goetz is the recipient of a NINCDS Teacher-Investigator Award.

Presented in part at the thirty-sixth annual meeting of the American Academy of Neurology, Boston, MA, April, 1984.

Accepted for publication September 12, 1984.




This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
A Münchau and K P Bhatia
Pharmacological treatment of Parkinson's disease
Postgrad. Med. J., October 1, 2000; 76(900): 602 - 610.
[Full Text]

Home page
 NeurologyHome page
C. G. Goetz, L. Blasucci, and G. T. Stebbins
Switching dopamine agonists in advanced Parkinson's disease: Is rapid titration preferable to slow?
Neurology, April 1, 1999; 52(6): 1227 - 1227.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Yoshimura, E. Mizuta, O. Yoshida, and S. Kuno
Therapeutic Effects of Dopamine D1/D2 Receptor Agonists on Detrusor Hyperreflexia in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Parkinsonian Cynomolgus Monkeys
J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 228 - 233.
[Abstract] [Full Text]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
H Baas, A G Beiske, J Ghika, M Jackson, W H Oertel, W Poewe, and G Ransmayr
Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
J. Neurol. Neurosurg. Psychiatry, October 1, 1997; 63(4): 421 - 428.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by AAN Enterprises, Inc.